Sign in
Morgan Lamberti

Morgan Lamberti

Research Analyst at Goldman Sachs Group Inc.

New York, NY, US

Morgan Lamberti is an Equity Research Associate at Goldman Sachs, specializing in biotechnology sector coverage with a focus on companies such as Krystal Biotech. As part of the equity research team, Lamberti supports senior analysts in producing actionable investment insights and financial analysis, contributing to coverage of high-performing biotech firms. Lamberti began working at Goldman Sachs after completing advanced academic training, and currently leverages a strong analytical background to deliver research that informs investment decisions. Morgan Lamberti holds FINRA registration as a broker and meets the regulatory requirements for securities research roles.

Morgan Lamberti's questions to Krystal Biotech (KRYS) leadership

Question · Q2 2025

Morgan Lamberti from Goldman Sachs asked if the Japan launch would require an initial healthcare practitioner visit and requested details on the fifth patient dosed in the AATD study.

Answer

Chairman & CEO Krish Krishnan confirmed the Japan launch process is similar to Europe, requiring an initial physician visit. President of R&D Suma Krishnan noted that across all three bronchoscopy patients, they saw robust expression in biopsy samples, and in two of those patients, they were able to measure AAT in the lavage and see a reduction in neutrophil elastase.

Ask follow-up questions

Fintool

Fintool can predict Krystal Biotech logo KRYS's earnings beat/miss a week before the call

Let Fintool AI Agent track Morgan Lamberti for you

Get briefed when they ask questions on calls

Best AI Agent for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Try Fintool for free